Clinical trials: Mast Cell Disorder
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Myeloproliferative Disorders, Leukemia
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00993694
- Testing
- chemotherapy, dapsone, medical chart review
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt University
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).
- Trial name
- NCT03167216
- Testing
- Cromolyn Sodium, Cetirizine Hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Mast Cell Activation Syndrome
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.
- Trial name
- NCT05449444
- Testing
- Masitinib 4.5 mg/kg/day, Best supportive care, Masitinib 6.0 mg/kg/day
- Where
- 4 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- AB Science
Mastocytosis, Indolent Systemic
Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis
Mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs.
- Trial name
- DALY-MAST (NCT05923372)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse
ST-segment Elevation Myocardial Infarction (STEMI)
The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI
The purpose of this study was to evaluate the efficacy and safety of ketotifen (MC stabilizer) on the basis of standard treatment after primary PCI in STEMI patients.
- Trial name
- NCT05511831
- Testing
- Ketotifen Fumarate, standard treatment
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Hypersensitivity, Immediate, Autoinflammatory Syndromes
Pathogenesis of Physical Induced Urticarial Syndromes
Background: Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria).
- Conditions
- Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
- Trial name
- NCT00887939
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anaphylaxis, Mastocytosis
Analysis of the Role of IgE Proteoforms in Health and Disease
The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of…
- Conditions
- Anaphylaxis, Mastocytosis, X-linked Agammaglobulinaemia, Venom Allergy
- Trial name
- IgE-PhD (NCT07328178)
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Systemic Mastocytosis
Evaluation of Response of Dasatinib to Treat Mastocytosis
This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib.
- Trial name
- NCT00979160
- Testing
- Dasatinib
- Where
- 12 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Federico II University
Leukemia, Myelodysplastic Syndromes
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00996047
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Where
- 280 sites in United States
- Volunteers
- 3,341 people
- Sponsor
- SWOG Cancer Research Network
Indolent Systemic Mastocytosis
Midostaurin in Indolent Systemic Mastocytosis
Rationale: Patients with indolent or smoldering systemic mastocytosis can have severe disabling symptoms. Almost all patients have fatigue, a compromised quality of life, hampering normal functioning.
- Trial name
- NCT01920204
- Testing
- Midostaurin,
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who…
- Trial name
- NCT06915766
- Testing
- Bezuclastinib
- Where
- 23 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Indolent Systemic Mastocytosis
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany.
- Trial name
- NCT07255638
- Testing
- Avapritinib
- Where
- 12 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Blueprint Medicines Corporation
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Ehlers Danlos Hypermobile Syndrome
Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders
The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.
- Trial name
- SAMED (NCT05382169)
- Testing
- Determine the presence of mast cell activation syndrome
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Lille Catholic University
Anemia, Sickle Cell
MAST - Magnesium for Sickle Cell Acute Crisis in Children
The purpose of this study is to determine if intravenous magnesium sulfate treatment is effective in reducing the length of stay and pain in children with sickle cell disease suffering an acute vaso-occlusive episode.
- Trial name
- NCT00313963
- Testing
- Magnesium Sulfate, Normal Saline
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- The Hospital for Sick Children
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center